I am an Internist and Pediatrician now trained in Pediatric Infectious Diseases. I provide clinical care and teaching on the Pediatric Infectious Diseases Consult Service at Stanford University and I am a Medical Officer with the Tuberculosis Control Branch at the California Department of Public Health. There I provide clinical consultation on the MDR TB consult service and TB clinic in addition to contributing to outbreak control and policy. My prior research, in the lab of Dr. Catherine Blish, was directed toward refining our understanding of anti-viral immunity and systemic immune changes that occur during pregnancy. Throughout my career I have focused on improving care for underserved populations and have a special interest in Pediatric HIV and TB in resource-limited settings.
- Pediatric Infectious Disease
Clinical Instructor, Pediatrics - Infectious Diseases
Fellowship:Stanford University (2014) CAUnited States of America
Board Certification: Pediatrics, American Board of Pediatrics (2010)
Board Certification: Internal Medicine, American Board of Internal Medicine (2009)
Residency:Maine Medical Center (2009) ME
Medical Education:University of Connecticut School of Medicine (2005) CTUnited States of America
- Immunogenicity and clinical efficacy of influenza vaccination in pregnancy FRONTIERS IN IMMUNOLOGY 2015; 6: 1-9
- Delayed BCG vaccination--time to take a shot. journal of infectious diseases 2015; 211 (3): 335-337
Pregnancy Does Not Attenuate the Antibody or Plasmablast Response to Inactivated Influenza Vaccine.
The Journal of infectious diseases
Inactivated influenza vaccine (IIV) is recommended during pregnancy to prevent influenza infection and its complications in pregnant women and their infants. However, the extent to which pregnancy modifies the antibody response to vaccination remains unclear, and prior studies have focused primarily on hemagglutinin inhibition (HI) titers. A more comprehensive understanding of how pregnancy modifies the humoral immune response to influenza vaccination will aid in maximizing vaccine efficacy. Healthy pregnant women and control women were studied prior to, 7 days after, and 28 days after vaccination with IIV. HI titers, microneutralization (MN) titers, and the frequency of circulating plasmablasts were evaluated in pregnant versus control women. Pregnant women and control women mount similarly robust serologic immune responses to IIV, with no significant differences for any influenza strain in postvaccination geometric mean HI or MN titers. HI and MN titers correlate, though MN titers demonstrate more robust changes pre- versus postvaccination. The induction of circulating plasmablasts is increased in pregnant women versus controls (median fold-change 2.60 vs 1.49 [interquartile range, 0.94-7.53 vs 0.63-2.67]; P = .03). Pregnant women do not have impaired humoral immune responses to IIV and may have increased circulating plasmablast production compared to control women.
View details for DOI 10.1093/infdis/jiv138
View details for PubMedID 25740957
- Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2014; 111 (40): 14506-14511